Background: Methotrexate (MTX) is widely used as a cytotoxic chemotherapeutic agent for malignancies as well as in the treatment of various inflammatory diseases. MTX treatment has been associated with hepatic toxicity and genotoxicity. The current study was conducted to assess the potential protective role of N-acetylcysteine in attenuation of methotrexate-induced hepatic damage and genotoxicity in MTX intoxicated male albino rats.
INTRODUCTION
Methotrexate was used as part of combination chemotherapy regimens to treat many kinds of cancers. Moreover, it has been used as a treatment for some autoimmune diseases, including Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and scleroderma (Klareskog et al., 2004).
The mechanism of liver injury with methotrexate is believed to be through inhibition of RNA and DNA synthesis in the liver and producing cellular Egypt J. Forensic Sci. Appli. Toxicol
Vol 16 (1) June 2016 arrest. Methotrexate is well known to cause elevations in serum aminotransferase levels, with high dose intravenous methotrexate, serum ALT levels can rise to 10 to 20 times the upper limit of normal (ULN) within 12 to 48 hours, on the other hand, with progress of time levels then fall rapidly to normal with only rare instances of jaundice or symptoms of liver injury. With long term use of low-to-moderate dose methotrexate therapy, elevations in serum ALT or AST values occur in 15 to 50% of patients. Approximately 5% of patients have elevations greater than twice normal and these abnormalities resolve rapidly with discontinuation or dose modification.Furthermore, long term therapy has been linked to development of fatty liver disease, fibrosis and cirrhosis (Reuben, 2007) .
Long term therapy with methotrexate has been associated with development of fatty liver, hepatic fibrosis and, in rare instances, portal hypertension, symptomatic cirrhosis and cytogenetic damage. (Chabner et al., 2011) .
N-acetyl-cysteine (NAC) is the acetylated form of L-cysteine. It has an impressive list of protective effects including: antioxidant activity, decrease of the biologically effective dose of carcinogens, anti-inflammatory activity, immunological effects, inhibition of progression to malignancy and metastasis, cytogenetic protective effects and protection from the adverse effects of chemopreventive and chemotherapeutic agents. (Sklar and Subramaniam, 2004) .
A small pilot study of chronic hepatitis C gave a promise that the addition of NAC to conventional therapy with interferon-α might make the treatment more effective, but a larger multicentre trial in Spain and Italy came to the opposite conclusion (Selzner et al., 2003) . Forty, apparently healthy, adult male albino rats (150+10 gm body weight) were obtained from Animal house of Faculty of Medicine-Cairo University. They were housed in hygienic metal cages and kept in a clean well ventilated room. They were fed on standard laboratory diet and allowed free access to water. Rats were left for two weeks before commencement of the study to be acclimatized to lab conditions. All rats were weighed weekly in order to adjust the dose of drugs according to body weight. All doses were given once daily for 12 weeks. 
METHODS

RESULTS
No difference was observed between the negative and positive control groups concerning the ALT levels.
At the end of the fourth week, the ALT level of the Methotrexate-treated group (group 3) increased about 3.46 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine (group 4), the ALT level decreased significantly about 11.88% as compared to that of the Methotrexate-treated group, but still 3 times higher than that of the negative control group (P< 0.000). At the end of the eighth week, the ALT level of the Methotrexate-treated group (group 3) increased about 3.68 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteinetreated group (group 4), the ALT level decreased significantly about 23.3% as compared to that of the Methotrexatetreated group, but still 2.82 times higher than that of the negative control group (P< 0.000). At the end of the twelve weeks, the ALT level of the Methotrexate-treated group increased about 3.76 times than that of the negative control group (P< 0.000). With the use of the N-acetylcysteine (group 4), the ALT level decreased significantly by 34.7% as compared to that of the Methotrexate-treated group (group 5) , but still it was about 2.45 times higher than that of the negative control group (P< 0.000). A significant constant increase of the ALT level of the Methotrexatetreated group (group 3) was observed throughout the study.
The level increased about 5% at the end of 8 th week and became about 10.4% more at the end of 12 th week as compared to its similarity of the 4 th week. In the Nacetylcysteine-treated group (group 4), the ALT level decreased about 8.6% at the end of 8 th week and became about 18% less at the end of 12 th week as compared to its similarity of the 4 th week-treated group (Table 1) .
No difference was observed between the negative and positive control groups concerning the BAX levels.
At the end of the fourth week, the BAX level of the Methotrexate-treated group (group 3) increased about 6.5 times than that of the negative control group (P< 0.000). In the Nacetylcysteine-treated group (group 4), the BAX level decreased significantly about 23.1% as compared to that of the Methotrexate-treated group, but still it was about 5 times higher than that of the negative control group (P< 0.000). At the end of the eighth week, the BAX level of the Methotrexate-treated group (group 3) increased about 9.16 times than that of the negative control group (P< 0.000). With the use of the Nacetylcysteine (group 4), the BAX level decreased significantly about 45.45% as compared to that of the Methotrexate-treated group, but still 5 times higher than that of the negative control group (P< 0.000). At the end of twelve weeks, the BAX level of the Methotrexate-treated group (group 3) was about 9.57 times higher than that of the negative control group (P< 0.000). With the use of the Nacetylcysteine (group 4) , the BAX level decreased significantly about 62.6% as compared to that of the Methotrexate-treated group, but it was 3.57 times higher than that of the negative control group (P< 0.000). A significant constant increase in the level of BAX of the Methotrexatetreated group (group 3) was observed throughout the study.
The level increased about 20.8% at the end of 8 th weekand became about 48.3% more at the end of 12 th week as compared to its similarity of the 4 th week. In the N-acetylcysteine-treated group (group 4), the BAX decreased about 14.2% at the end of 8 th week and became about 28.5% less at the end of 12 th week as compared to its similarity of the 4 th week-treated group (Table 2) 
DISCUSSION
The purpose of this study was to test the protective effect of N-acetyl cysteine on Methotrexate induced hepatic toxicity in albino rats.
In the current study, the ALT levels of the methotrexate-treated group (group 3) increased about 3. 46, 3.68 and 3.76 In conclusion, the current study showed that NAC has a good protective effect against the hepatic damage and genotoxicity induced by MTX in rats. the hepatic damage and genotoxicity induced by MTX in rats.
In the view of the present study, we recommend to conduct the same study on human beings in order to investigate the feasibility and suitability of the results of the present study on human beings.
